Want to see IMRX full AI Analyst Report?
IMRX Stock Chart & Stats
$5.15
$0.04(0.93%)
At close: 4:00 PM EDT
$5.15
$0.04(0.93%)
Day’s Range― - ―
52-Week Range$3.86 - $10.08
Previous Close$4.39
Volume459.78K
Average Volume (3M)628.53K
Market Cap
$313.78M
Enterprise Value$176.57
Total Cash (Recent Filing)$149.90M
Total Debt (Recent Filing)$3.63M
Price to Earnings (P/E)―
Beta2.08
Next Earnings
Nov 05, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding64,697,400
10 Day Avg. Volume557,545
30 Day Avg. Volume628,531
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.33
Price to Sales (P/S)0.00
P/FCF Ratio-6.37
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$14.60Price Target Upside183.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.11
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Promising Atebimetinib Clinical DataThe lead program has shown encouraging efficacy and tolerability in pancreatic cancer, supporting advancement into a pivotal Phase 3 trial. If confirmed prospectively, these results could materially improve the company’s long-term commercial prospects.
Low Financial LeverageVery low leverage limits interest and refinancing pressure while substantial equity provides a financial cushion during clinical development. This gives Immuneering more flexibility than a similarly unprofitable biotech with significant debt obligations.
Expanding Oncology PipelineProgress beyond a single lead indication creates additional clinical and strategic pathways for value creation. A broader pipeline can reduce dependence on one trial and improve the potential for future partnerships or product revenue.
Bears Say
No Sustained Commercial RevenueImmuneering has not demonstrated recurring product revenue or commercial scale, leaving its financial outlook dependent on clinical success. Until a candidate is approved and adopted, earnings visibility and the ability to self-fund operations remain limited.
Persistent Operating LossesDeep, recurring losses reflect a costly R&D model without a commercial offset. Continued deficits can consume shareholder capital and require additional financing, while any delay or failure in development could extend the period before profitability.
Ongoing Cash Burn And Financing RiskPersistent negative operating and free cash flow means Immuneering primarily relies on external capital to fund trials and operations. This creates dilution or financing risk and could constrain development if capital markets or partners do not provide support.
Immuneering News
IMRX FAQ
What was Immuneering’s price range in the past 12 months?
Immuneering lowest stock price was $3.86 and its highest was $10.08 in the past 12 months.
What is Immuneering’s market cap?
Immuneering’s market cap is $313.78M.
When is Immuneering’s upcoming earnings report date?
Immuneering’s upcoming earnings report date is Nov 05, 2026 which is in 63 days.
How were Immuneering’s earnings last quarter?
Immuneering released its earnings results on Aug 05, 2026. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.264 by -$0.006.
Is Immuneering overvalued?
According to Wall Street analysts Immuneering’s price is currently Undervalued.
Does Immuneering pay dividends?
Immuneering does not currently pay dividends.
What is Immuneering’s EPS estimate?
Immuneering’s EPS estimate is -0.31.
How many shares outstanding does Immuneering have?
Immuneering has 64,697,400 shares outstanding.
What happened to Immuneering’s price movement after its last earnings report?
Immuneering reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.264. Following the earnings report the stock price went down -0.227%.
Which hedge fund is a major shareholder of Immuneering?
Currently, no hedge funds are holding shares in IMRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immuneering Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.60 (183.50% Upside)
$14.60 (183.50% Upside)
Blogger Sentiment
Bullish
IMRX Sentiment 100%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Increased
By 88.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $36.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 2.3%
Last 30 Days ▲ 2.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.65%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
404.43%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Immuneering
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
IMRX Stock 12 Month Forecast
Average Price Target
$14.60
▲(183.50% Upside)
Technical Analysis
Ownership Overview
9.38% Insiders
15.57% Mutual Funds
9.33% Other Institutional Investors
56.81% Public Companies and
Individual Investors